Navigation Links
Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin(R) Program at ASH Annual Meeting
Date:12/13/2011

SAN DIEGO, California, December 13, 2011 /PRNewswire/ --

-- Breadth of Pharmacokinetic Data Points to Tunable Half-life for Platform --

Pieris AG presented novel preclinical in vitro and in vivo data for its PRS-080 Anticalin hepcidin antagonist in an oral presentation at the American Society of Hematology Annual Meeting, the company announced today.  In a presentation entitled "Discovery and Preclinical Characterization of a Novel Hepcidin Antagonist with Tunable PK/PD Properties for the Treatment of Anemia in Different Patient Populations", the results demonstrated Pieris' PRS-080's ability to increase the serum iron levels in preclinical models by binding the hepcidin target with high affinity and specificity, while offering the flexibility of a tunable pharmacokinetic (PK) and pharmacodynamic (PD) profile.

"These studies in multiple preclinical species and models demonstrate the high level of control offered by the Anticalin approach in combination with PEGylation to create 'fit for purpose' PK/PD profiles that can match specific target biology across different patient populations," stated Laurent Audoly, Ph.D., Chief Scientific Officer of Pieris.  "In particular, the clear relationship between PEG formats and the resulting PK/PD profile for several PRS-080 variants tested in animal models provides an extremely encouraging basis for a rapid advance toward the clinic and creates a portfolio of molecules adapted for different hepcidin-dependent diseases."

The presentation at ASH included several in vivo animal studies of PRS-080's sub-nanomolar potency in binding hepcidin, which is a small peptide that plays a pivotal role in the regulation of iron levels in the blood.  In addition, Pieris researchers documented reliable drug half-life levels dependent on the size of the PEGylated compound.  In several preclinical models, a single dose of four different formulations of PRS-080 showed clear correlation between the PEGylation size and the pharmacokinetic properties.  Based on these data and the clinical experience from a recently completed Phase I trial with a separate compound, PRS-050, Pieris researchers predict a high level of confidence in defining the best half-life profile for treating anemia in patients.  The lead PRS-080 program candidate is projected to enter human clinical trials in the first half of 2013.

Hepcidin is a liver-derived peptide that regulates iron homeostasis in the blood. Produced in response to iron overload and inflammation, hepcidin decreases iron absorption.  When over-expressed, the peptide is associated with the development of anemia, often the result of chronic kidney disease, cancer, cancer treatments such as chemotherapy, and other inflammatory diseases.

Anticalins are therapeutic proteins derived from human lipocalins, rationally engineered to solve for the pharmacological and pharmaceutical limitations of both protein and non-protein based drug platforms.

About Pieris

Pieris AG is an independent, clinical-staged biotechnology company advancing its proprietary Anticalin® technology to create differentiated drugs that are safer and more effective than conventional approaches.  Exclusive to Pieris, Anticalin-based drugs promise to address high-unmet medical needs and expand the therapeutic potential of current targeted approaches.  Pieris' pipeline ranges from its lead compound, PRS-050 (anti-VEGF, oncology) that recently completed a Phase I clinical trial, to multiple Anticalins in preclinical development across a range of therapeutic areas.  The company has four ongoing discovery and development collaborations: Daiichi Sankyo, Takeda San Francisco, the Sanofi Group and Allergan.  Privately held, Pieris has been funded by premier biotechnology-focused venture capital, including lead investors OrbiMed Advisors and Global Life Science Ventures. For more information, please visit: http://www.pieris-ag.com.

 

For further information, please contact:

Dr. Andreas Hohlbaum
Vice President, Strategic Research and Project Management
Pieris AG
or
Gretchen Schweitzer
+49-172-861-8540
media@pieris-ag.com

Additional information is available at http://www.pieris-ag.com.

Anticalin®, Anticalins® are registered trademarks of Pieris AG.



'/>"/>
SOURCE Pieris AG
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050
2. Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist
3. Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
4. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
11. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... Research and Markets has announced the addition of the  "Market ... to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Emission Tomography (PET) scanner and cyclotron install base in the ... France , Germany , ... United Kingdom . Along with the current ...
(Date:5/5/2016)... , May 5, 2016 ... addition of the  "Europe Thalassaemia Market and ... their offering.       (Logo: ... Europe Thalassaemia Market and Competitive Landscape Highlights ... pipeline products, Thalassaemia epidemiology, Thalassaemia market valuations ...
(Date:5/4/2016)... 2016 According to a new ... Interface Market - Global Industry Analysis, Size, Share, Growth, ... interface (BCI) market  is expected to reach a value ... to expand at a CAGR of 14.9 % during ... A BCI device provides collaboration between the brain and ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... May 06, 2016 , ... This Mother’s Day kicks off the start of ... National Women’s Health Week takes place May 8-May 14. , Throughout the ... to empower women to make their health a top priority. Women everywhere are being ...
(Date:5/6/2016)... ... May 06, 2016 , ... “ Crossing Over: Affirmations of Faith ... dying patients who have allowed those holding vigil to glimpse into the supernatural as ... hopes to help readers spiritually and practically gain insight into providing care to terminal ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... TransWipe Volume ... Cut Pro X. Drag and drop a TransWipe preset between two video clips to ... smooth corner wipes to colored panels with customizable color and orientation options. TransWipe Volume ...
(Date:5/5/2016)... ... 05, 2016 , ... Pivot Point Consulting achieved ... KLAS Performance Report, Epic Consulting 2016 - Which Firms Provide Breadth, ... consulting services for electronic health record (EHR) solutions from Epic Systems Corporation ...
(Date:5/5/2016)... Lubbock, Texas (PRWEB) , ... May 05, 2016 , ... ... of the Responsible Wool Standard (RWS) for public stakeholder review. The stakeholder review is ... ensure that it meets its goals and delivers value to the wool industry., The ...
Breaking Medicine News(10 mins):